ライフサイエンスコーパス: adenosine kinase

1 ) and 417 microbial KEGG genes (e.g., K00856-adenosine kinase).

2 antly potentiated by substrate inhibition of adenosine kinase.

3 nterplay between nucleoside transporters and adenosine kinase.

4 ansporter and is a substrate of T. b. brucei adenosine kinase.

5 intractable epilepsy demonstrated increased adenosine kinase.

6 excellent subversive substrate of T. gondii adenosine kinase.

7 f BTI as subversive substrates for T. gondii adenosine kinase.

8 The adenosine kinase activity in dorsal root ganglion cultur

9 Furthermore, an alteration of adenosine kinase activity modifies the degree of this in

10 itiation of toxicity in sympathetic neurons, adenosine kinase activity was compared in sensory and sy

11 Furthermore, both adenosine deaminase and adenosine kinase activity was significantly diminished (

12 posure to DEA/NO nearly completely inhibited adenosine kinase activity.

13 e levels with a combination of inhibitors of adenosine kinase, adenosine deaminase, and the equilibra

14 suppress local silencing by interacting with adenosine kinase (ADK) and can suppress basal defense by

15 ABP4 forms a functional hormone complex with adenosine kinase (ADK) and nucleoside diphosphate kinase

16 Adenosine kinase (ADK) catalyzes the phosphorylation of

17 Adenosine kinase (ADK) deficiency in human patients (OMI

18 Adenosine kinase (ADK) from Mycobacterium tuberculosis (

19 M #614300) that is based on mutations in the adenosine kinase (Adk) gene has been discovered recently

20 ilencing by a mechanism that correlates with adenosine kinase (ADK) inhibition, while AL2 in addition

21 Adenosine kinase (AdK) inhibitors raise endogenous adeno

22 Adenosine kinase (ADK) is a key enzyme that regulates in

23 ntracellular adenosine and its key regulator adenosine kinase (ADK) play important roles in vascular

24 ing adenosine in the purine salvage pathway, adenosine kinase (ADK) regulates methylation reactions.

25 ich involves interacting with and inhibiting adenosine kinase (ADK), a cellular enzyme associated wit

26 viral proteins interact with and inactivate adenosine kinase (ADK), a cellular enzyme important for

27 Here we show that astrocyte-expressed adenosine kinase (ADK), a key negative regulator of the

28 viral proteins interact with and inactivate adenosine kinase (ADK), a nucleoside kinase that catalyz

29 at the compound 5'-iodotubercidin suppresses adenosine kinase (ADK), an energy pathway enzyme, and al

30 of adenosine by pharmacologic inhibition of adenosine kinase (ADK), the key enzyme of adenosine clea

31 Adenosine kinase (ADK), the major adenosine-metabolizing

32 After phosphorylation by adenosine kinase (ADK), they undergo deamination by aden

33 AL2 and L2 interact with and inactivate adenosine kinase (ADK), which is required for efficient

34 s shown to decrease expression of the enzyme adenosine kinase (Adk), which is responsible for clearin

35 The regulation of adenosine kinase (AK) activity has the potential to cont

36 bercidin" analogues are potent inhibitors of adenosine kinase (AK) and are orally active in animal mo

37 -702 is a novel and selective non-nucleoside adenosine kinase (AK) inhibitor that produces increases

38 rted that analogues of tubercidin are potent adenosine kinase (AK) inhibitors with antiseizure activi

39 Adenosine kinase (AK) is a key enzyme in the regulation

40 Adenosine kinase (AK) is a key purine metabolic enzyme f

41 Adenosine kinase (AK) is a purine salvage enzyme that ca

42 Adenosine kinase (AK) is an enzyme responsible for conve

43 resistant clones exhibited disruption of the adenosine kinase (AK) locus, others displayed normal AK

44 denine phosphoribosyltransferase (APRT), and adenosine kinase (AK) to purine salvage in Leishmania do

45 ne (ADO) can be raised through inhibition of adenosine kinase (AK), a primary metabolic enzyme for AD

46 the activities of adenosine deaminase (ADA), adenosine kinase (AK), and inosine monophosphate-specifi

47 DO can be enhanced consists of inhibition of adenosine kinase (AK), the primary metabolic enzyme for

48 Inhibition of adenosine kinase (AK), the primary metabolic enzyme for

49 anine phosphoribosyltransferase (HXGPRT) and adenosine kinase (AK).

50 ll fold is similar to that of ribokinase and adenosine kinase, although sequence similarity is not im

51 virin, and both compounds are substrates for adenosine kinase, an enzyme critical for conversion to t

52 Also, adenosine kinase and 60S ribosomal protein were confirme

53 dogenous adenosine produced by inhibition of adenosine kinase and adenosine deaminase.

54 on the recycling of adenosine back to ATP by adenosine kinase and adenylate kinase.

55 Inhibition of adenosine kinase and deoxycytidine kinase prevented the

56 8-Cl-Ado activity is dependent on adenosine kinase and requires intracellular accumulation

57 Unlike adenosine kinase and ribokinase, in which the active sit

58 veals that the P2 nucleoside transporter and adenosine kinase are involved in the uptake and activati

59 e substrates of T. gondii,but not the human, adenosine kinase are preferentially metabolized to their

60 he (redundant) purine salvage pathway enzyme adenosine kinase are susceptible to the drug, with an IC

61 orylation of one or more proteins other than adenosine kinase as a consequence of NMDA receptor activ

62 efflux of adenosine resulting from block of adenosine kinase at only a subset of synapses.

63 sine facilitates and that inhibition of ADK (adenosine kinase) augments conducted vasodilation for a

64 the activity of both adenosine deaminase and adenosine kinase (both p </= .0001).

65 P. falciparum lacks adenosine kinase but can salvage AMP synthesized in the

66 The inhibition of adenosine kinase by 5-iodotubercidin increased the extra

67 We observed the repression of adenosine kinase by proinflammatory cytokines and found

68 We determined the structure of human adenosine kinase by X-ray crystallography using MAD phas

69 Adenosine kinase catalyzes the phosphorylation of adenos

70 Studies in an adenosine kinase deficient cell line showed that the 6-N

71 nosine accumulates high levels of dATP in an adenosine kinase-dependent process and dies within a few

72 We tested the expression of adenosine kinase during inflammatory stimulation in vitr

73 -monophosphate (AMP) catalyzed by the enzyme adenosine kinase (EC 2.7.1.20).

74 ized and evaluated against Toxoplasma gondii adenosine kinase (EC.2.7.1.20).

75 Inhibitors of adenosine kinase elevate adenosine to levels that activa

76 ects of iodotubercidin (ITU, an inhibitor of adenosine kinase), erythro-9-(2-hydroxy-3-nonyl)adenine

77 ad to endothelial inflammation by increasing adenosine kinase expression, and that its knockdown in e

78 ocked with 5-iodotubercidin, an inhibitor of adenosine kinase, folate transport stimulation by AICAR

79 The high-affinity adenosine kinase from Anopheles gambiae efficiently conv

80 osine by biallelic genetic disruption of the adenosine kinase gene (Adk-/-), and respective wild-type

81 On the basis of the evidence of the role of adenosine kinase in regulating adenosine levels during h

82 Adenosine kinase in T. gondii is significantly more acti

83 The inhibition of adenosine kinase in vivo showed protective properties, r

84 We found different adenosine kinase-inactivating (ADK-inactivating) alterat

85 The hypothermia elicited by adenosine kinase inhibition (with A134974), inosine, or

86 ndogenous adenosine levels through selective adenosine kinase inhibition produces powerful analgesic

87 ed adenosine accumulation is associated with adenosine kinase inhibition.

88 viously has been shown to be associated with adenosine kinase inhibition.

89 phosphatase 1/2A did not abolish NMDA-evoked adenosine kinase inhibition.

90 ced by treatment of rats with ethanol and an adenosine kinase inhibitor (ABT702).

91 -deficient cultures were also rescued by the adenosine kinase inhibitor 5'-amino-5'-deoxyadenosine (5

92 Moreover, an adenosine kinase inhibitor 5'-iodotubercidin, which effe

93 In contrast, the selective adenosine kinase inhibitor 5-iodotubercidin (5-IT; 10 mi

94 or inhibition of AICAR conversion to ZMP by adenosine kinase inhibitor 5-iodotubercidin.

95 Treatment with the adenosine kinase inhibitor 5-iodotubericidin to inhibit

96 ptive effects of AMP, when combined with the adenosine kinase inhibitor 5-iodotubericidin, were reduc

97 w that 5-iodotubercidin (5-IT), an annotated adenosine kinase inhibitor previously reported to increa

98 transport blocker); and (3) iodotubericidin (adenosine kinase inhibitor).

99 The adenosine kinase inhibitor, 5-iodotubercidin (10 microme

100 In contrast, the adenosine kinase inhibitor, 5-iodotubericidin, which inh

101 enzoxy-Val-Ala-Asp-fluoromethyl ketone or an adenosine kinase inhibitor, but not in cultures with fet

102 romo-pyrazolo [3,4-d] pyrimidine, a specific adenosine kinase inhibitor-as well as continuous intra-a

103 platform, we identify a class of compounds [adenosine kinase inhibitors (ADK-Is)] that promote repli

104 As an alternative, we explored the use of adenosine kinase inhibitors (AKIs) as potential antiseiz

105 We previously demonstrated that adenosine kinase inhibitors (AKIs) exhibit antiinflammat

106 Adenosine kinase inhibitors (AKIs) represent an alternat

107 ucleosides were synthesized and evaluated as adenosine kinase inhibitors (AKIs).

108 ido[2,3-d]pyrimidines as novel nonnucleoside adenosine kinase inhibitors is described.

109 Thus, adenosine kinase is a structurally distinct mammalian nu

110 Taken together, these data show that adenosine kinase is a valuable target for reducing the i

111 deaminase blockade but not when erythrocyte adenosine kinase is also inhibited.

112 It has been found previously that adenosine kinase is inhibited by its substrate, adenosin

113 However, adenosine kinase is not a direct substrate for phosphata

114 ibility that in our system the inhibition of adenosine kinase is related to an increase in intracellu

115 Wild-type and adenosine kinase+/- mice were subjected to lipopolysacch

116 In vitro cell lines, wild-type and adenosine kinase+/- mice.

117 s during hypoxia, we evaluated the effect of adenosine kinase on lung injury.

118 ence of a pharmacologic approach to blocking adenosine kinase on the extent of lung injury.

119 een shown that the activity of intracellular adenosine kinase preferentially controls the activation

120 Studies using the adenosine kinase promoter were performed in vitro.

121 er of activated B-cells on regulation of the adenosine kinase promoter.

122 Mice with endogenous adenosine kinase repression (adenosine kinase+/-) showed

123 nd ADO1, encoding an adenylate kinase and an adenosine kinase, respectively, negatively regulate PHO5

124 with endogenous adenosine kinase repression (adenosine kinase+/-) showed reduced infiltration of leuk

125 ied and incorporated into lead inhibitors of adenosine kinase that exhibited potent in vitro and in v

126 ot analysis demonstrated that the KD reduced adenosine kinase, the major adenosine-metabolizing enzym

127 hen FTOC were performed with an inhibitor of adenosine kinase, the major thymic deoxyadenosine phosph

128 lar to that proposed for both ribokinase and adenosine kinase, ThiK lacks an absolutely conserved Asp

129 Pharmacologic inhibition of adenosine kinase was performed in vitro, and its effect

130 Adenosine kinase was the major determinant of adenosine

131 th cDNA clones encoding catalytically active adenosine kinase were obtained from lymphocyte, placenta

132 ne deposition, homologous recombination, and adenosine kinase, which influences the methionine cycle.

133 n of analogues that are potent inhibitors of adenosine kinase with in vivo analgesic activity.